Vir Biotech soars as collaborates with Eli Lilly on COVID-19 antibody treatment
27/01/2021 16:57
** Vir Biotechnology Inc VIR.O shares up 40.6% to $108.82
after announcement Eli Lilly LLY.O testing its COVID-19
antibody therapy with Vir's drug, to help battle new variants of
the coronavirus
** VIR shares soar as much as 82% to fresh record high
$141.01 on Weds
** Collaboration, including Vir's partner GlaxoSmithKline
GSK.L , marks first time monoclonal antibodies from separate
cos will be tested together, cos said on Weds urn:newsml:reuters.com:*:nL4N2K22VA
** A study based on laboratory tests showed COVID-19
antibody drugs made by LLY may be less effective against new
coronavirus variant found in South Africa urn:newsml:reuters.com:*:nL4N2K21MJ
** VIR shares adding to 74% surge on Tues after co reported
positive data from liver infection antibody trial urn:newsml:reuters.com:*:nL4N2K13DZ
** With move on Weds, VIR has quadrupled YTD
** LLY shares on Weds down 2.3% to $207.86
(Lance Tupper is a Reuters market analyst. The views expressed
are his own)
((lance.tupper.tr.com@reuters.net
lance.tupper@tr.com 1-332-219-1430))